Photocure ASA 2023 AR2
The report highlights Photocure's strong financial and operational performance in 2023, achieving a 27% revenue growth to NOK 500.7 million and generating NOK 55.5 million in EBITDA. The company expanded its commercial footprint by installing a record number of rigid blue light cystoscopy (BLC) towers in the U.S. and upgrading image quality in 25% of its European target accounts. In sustainability, Photocure implemented its first group environmental policy and maintained its commitment to the UN Global Compact. The company also successfully completed a Phase III trial for Hexvix in China with partner Asieris, leading to a New Drug Application submission.
Company: Photocure ASA
Sector: Health Care
Country: Norway
Year: 2023
Type: AR2
Pages: 124
Photocure ASA
Annual Report
The report highlights Photocure's strong financial and operational performance in 2023, achieving a 27% revenue growth to NOK 500.7 million and generating NOK 55.5 million in EBITDA. The company expanded its commercial footprint by installing a record number of rigid blue light cystoscopy (BLC) towers in the U.S. and upgrading image quality in 25% of its European target accounts. In sustainability, Photocure implemented its first group environmental policy and maintained its commitment to the UN Global Compact. The company also successfully completed a Phase III trial for Hexvix in China with partner Asieris, leading to a New Drug Application submission.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees